nach oben

European Journal of Pediatrics

Erschienen in:

29.12.2017 | Review

Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence

verfasst von: Werner Keenswijk, Ann Raes, Johan Vande Walle

Erschienen in: European Journal of Pediatrics | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Severe complications due to Shigatoxin-associated hemolytic uremic syndrome (STEC-HUS) currently present a serious challenge since no specific treatment for this condition is available. Eculizumab, a terminal complement inhibitor, has been used especially in STEC-HUS patients with severe neurological involvement, but the efficacy remains undetermined. In order to determine its efficacy, we searched the databases Pubmed, Web of Science, Embase, and LiLACS for reports describing outcomes of eculizumab administration in STEC-HUS. We retrieved 11 reports ranging from case reports to cohort studies with the largest study population emanating from the 2011 German outbreak. Outcomes were variable and difficult to interpret in light of the absence of high-quality studies but seemed to point towards potential efficacy of eculizumab if administered early in the course.

Conclusion: The efficacy of eculizumab in STEC-HUS could not be established nor disproven based on current data, and there is a desperate need for randomized controlled trials.

What is known?

• Eculizumab has been used in complicated cases of Shigatoxin-associated hemolytic uremic syndrome but the efficacy remains unknown?

What is new?

• Eculizumab might be efficacious if given early in selected cases of Shigatoxin-associated hemolytic uremic syndrome; however, randomized trials are needed to assess this.

Nguyen Y, Sperandio V (2012) Enterohemorrhagic E. coli (EHEC) pathogenesis. Front Cell Infect Microbiol 2:90CrossRefPubMedPubMedCentral

Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. JASN 16(4):1035–1050. https://doi.org/10.1681/ASN.2004100861 CrossRefPubMed

Scheiring J, Andreoli SP, Zimmerhackl LB (2008) Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 23(10):1749–1760. https://doi.org/10.1007/s00467-008-0935-6 CrossRefPubMed

Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, Brun M, Ranchin B, Bandin F, Cloarec S, Bourdat-Michel G, Piètrement C, Champion G, Ulinski T, Deschênes G (2010) Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 5(7):1218–1228. https://doi.org/10.2215/CJN.08921209 CrossRefPubMedPubMedCentral

Nester CM, Thomas CP (2012) Atypical hemolytic uremic syndrome: what is it, how is it diagnosed and how is it treated? Hematol Am Soc Hematol Educ Program:617–612

Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F (2011) Eculizumab in severe Shiga-toxin associated HUS N. Engl J Med 364(26):2561–2563CrossRef

Keir LS, Marks SD, Kim JJ (2012) Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 6:195–208. https://doi.org/10.2147/DDDT.S25757 PubMedPubMedCentralCrossRef

Taylor CM, Monnens LA (1998) Advances in haemolytic uraemic syndrome. Arch Dis Child 78(2):190–193. https://doi.org/10.1136/adc.78.2.190 CrossRefPubMedPubMedCentral

Laurence J (2012) Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol 10(10 Suppl 17):1–12PubMed

10.

Conway EM (2015) HUS and the case for complement. Blood 126(18):2085–2090. https://doi.org/10.1182/blood-2015-03-569277 CrossRefPubMed

11.

Ståhl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117(20):5503–5513. https://doi.org/10.1182/blood-2010-09-309161 CrossRefPubMed

12.

Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C (2011) Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 187(1):172–180. https://doi.org/10.4049/jimmunol.1100491 CrossRefPubMed

13.

Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, Lämmle B (2012) Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 120(6):1157–1164. https://doi.org/10.1182/blood-2012-02-412197 CrossRefPubMedPubMedCentral

14.

Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4(12):1920–1924. https://doi.org/10.2215/CJN.02730409 CrossRefPubMedPubMedCentral

15.

Franchini M (2015) Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clin Chem Lab Med 53(11):1679–1688. https://doi.org/10.1515/cclm-2015-0024. CrossRefPubMed

16.

Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmüller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Münte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schöcklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhöner P, Wiesner M, Zeissig S, Büning J, Schiffer M, Kuehbacher T, EHEC-HUS consortium (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565CrossRefPubMedPubMedCentral

17.

Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753e9CrossRef

18.

Bauer A, Loos S, Wehrmann C, Horstmann D, Donnerstag F, Lemke J, Hillebrand G, Löbel U, Pape L, Haffner D, Bindt C, Ahlenstiel T, Melk A, Lehnhardt A, Kemper MJ, Oh J, Hartmann H (2014) Neurologial involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol 29(9):1607–1615. https://doi.org/10.1007/s00467-014-2803-x CrossRefPubMed

19.

Kielstein JT, Beutel G, Fleig S, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, Busch V, Ries W, Mitzner S, Mees S, Stracke S, Nürnberger J, Gerke P, Wiesner M, Sucke B, Abu-Tair M, Kribben A, Klause N, Schindler R, Merkel F, Schnatter S, Dorresteijn EM, Samuelsson O, Brunkhorst R, Collaborators of the DGfN STEC-HUS registry (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807e15

20.

Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, Hélou S, Bordes C, Reffet A, Llanas B, Skopinski S, Rolland P, Gruson D, Combe C (2012) Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 29:565–572CrossRef

21.

Ekinci Z, Kenan Bek K, Aytac MB, Karadenizli A, Hancer VS. Renal outcome with eculizumab in two diarrhea-associated hemolytic ureamic syndrome cases with severe neurologic involvement. Available at www.sciencedirect.com/science/article/pii/S1561541314000234 Accessed 14 Feb 2017

22.

Ekinci Z, Candan C, Alpay H, Horstmann D, Donnerstag F, Lemke J, Hillebrand G, Löbel U, Pape L, Haffner D, Bindt C, Ahlenstiel T, Melk A, Lehnhardt A, Kemper MJ, Oh J, Hartmann H (2013) Hemolytic uremic syndrome outbreak in Turkey in 2011. Turk J Pediatr 55(3):246–252PubMed

23.

Saini A, Emke AR, Silva MC, Perlman SJ (2015) Response to eculizumab in Escherichia coli O157: H7-induced hemolytic uremic syndrome with severe neurological manifestations. Clin Pediatr (Phila) 54(4):387–389. https://doi.org/10.1177/0009922814534520 CrossRef

24.

Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) with neurological involvement. Medicine (Baltimore) 94(24):e1000. https://doi.org/10.1097/MD.0000000000001000 CrossRefPubMed

25.

Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, Oualha M, Boddaert N, Salomon R, Desguerre I (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55(8):758–765. https://doi.org/10.1111/dmcn.12161 PubMedCrossRef

26.

Trachtman H, Austin C, Lewinski M, Stahl RA (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 8(11):658–669. https://doi.org/10.1038/nrneph.2012.196 CrossRefPubMed

27.

Navarro-Garcia F (2014) Escherichia coli O104:H4 pathogenesis: an Enteroaggregative E. coli/Shiga toxin-producing E. coli explosive cocktail of high virulence. Microbiol Spectr 2(6). https://doi.org/10.1128/microbiolspec.EHEC-0008-2013

28.

Oakes RS, Siegler RL, McReynolds MA, Pysher T, Pavia AT (2006) Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 117(5):1656–1662. https://doi.org/10.1542/peds.2005-0785 CrossRefPubMed

29.

Keenswijk W, Walle JV (2017) Atypical hemolytic uremic syndrome in low resource settings: which options do we have? Ther Apher Dial. https://doi.org/10.1111/1744-9987.12609

Titel: Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence
verfasst von: Werner Keenswijk
Ann Raes
Johan Vande Walle
Publikationsdatum: 29.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Pediatrics / Ausgabe 3/2018
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-017-3077-7

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2018

Changing characteristics of hospital admissions but not the children admitted—a whole population study between 2000 and 2013

Thyroid disease in children and adolescents with PTEN hamartoma tumor syndrome (PHTS)

Associations between metabolic syndrome components and markers of inflammation in Welsh school children

Provided information and parents’ comprehension at the time of admission of their child in pediatric intensive care unit

Impact of war on child health in northern Syria: the experience of Médecins Sans Frontières

Health status of Polish children and adolescents after cancer treatment

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie